Stay updated on Pembrolizumab for HNSCC Residual Disease Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for HNSCC Residual Disease Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T18:23:08.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2. Deleted the government funding lapse notice and related operating-status information (Revision: v3.4.1).
    Difference
    0.4%
    Check dated 2026-02-11T10:20:06.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a site-wide notice about funding-related status and updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T06:39:26.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The changes are minor UI and metadata updates, including a glossary toggle, updated QC-related labels such as 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', and removal of older labels. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T04:38:02.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.3.4, replacing Revision: v3.3.3. This appears to be a standard version update.
    Difference
    0.1%
    Check dated 2026-01-14T03:09:23.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    A unified Locations section has been added, listing Connecticut and Texas. The prior separate Connecticut Locations and Texas Locations sections were removed.
    Difference
    0.3%
    Check dated 2025-12-23T17:32:33.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for HNSCC Residual Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.